Filing Flows › Lifevantage (LFVN) › Q2 2026 › vs Q1 2026
Lifevantage (LFVN) Q2 2026 vs Q1 2026 (quarter over quarter)
Lifevantage's revenue fell $1.3M (-3%) from $43.7M in Q1 2026 to $42.4M in Q2 2026. The biggest changes: Life Vantage Product Line +$3.3M (+52%); Protandim −$899K (-5%); AXIO Product Line +$765K (+22%). Gross margin 78.0% against 79.0% (-1.0 pts).
Lifevantage, Q2 2026: revenue $42.4M (-23% year over year), operating margin 3.9%, net earnings $1.3M, operating cash flow $4.8M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 78.0% | 79.0% | -1.0 pts |
| Operating margin | 3.9% | 3.8% | +0.1 pts |
| Net margin | 3.0% | 3.1% | -0.1 pts |
| Free cash flow margin | 8.8% | 9.1% | -0.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Protandim | $19.1M | $20.0M | −$899K | -5% |
| Life Vantage Product Line | $9.6M | $6.3M | $3.3M | +52% |
| True Science Product Line | $9.0M | $8.9M | $115K | +1% |
| AXIO Product Line | $4.2M | $3.4M | $765K | +22% |
| Phys IQ Product Line | $667K | $847K | −$180K | -21% |
| Revenue | $42.4M | $43.7M | −$1.3M | -3% |
| Gross profit | $33.0M | $34.5M | −$1.5M | -4% |
| Cost of revenue | $9.3M | $9.2M | $162K | +2% |
| Operating profit | $1.7M | $1.7M | −$11K | -0.7% |
| Operating expenses | $31.4M | $32.9M | −$1.5M | -5% |
| Pre-tax earnings | $1.7M | $1.7M | $40K | +2% |
| Research & development | $200K | $200K | $0 | 0% |
| SG&A | $13.9M | $13.9M | $8K | +0.1% |
| Other operating costs | $17.3M | $18.8M | −$1.5M | -8% |
| Net earnings | $1.3M | $1.4M | −$83K | -6% |
| Income tax | $417K | $294K | $123K | +42% |
| Depreciation & amortization | $697K | $714K | −$17K | -2% |
| Share-based compensation | $263K | $704K | −$441K | -63% |
| Working capital & other | $2.5M | $2.2M | $320K | +14% |
| Operating cash flow | $4.8M | $5.0M | −$221K | -4% |
| Free cash flow (OCF − capex) | $3.7M | $4.0M | −$247K | -6% |
| Capital expenditures | $1.0M | $1.0M | $26K | +3% |
Questions
How much did Lifevantage's revenue grow quarter over quarter in Q2 2026?
Lifevantage's revenue fell $1.3M (-3%) from $43.7M in Q1 2026 to $42.4M in Q2 2026.
What drove Lifevantage's revenue change in Q2 2026?
Life Vantage Product Line +$3.3M (+52%); Protandim −$899K (-5%); AXIO Product Line +$765K (+22%).